LONHALA MAGNAIR KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6962151 | SUMITOMO PHARMA AM | Inhalation nebulizer |
Oct, 2020
(3 years ago) | |
| US7316067 | SUMITOMO PHARMA AM | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
Sep, 2022
(1 year, 7 months ago) | |
| US8511581 | SUMITOMO PHARMA AM | Fluid droplet production apparatus and method |
Nov, 2023
(5 months ago) | |
| US7458372 | SUMITOMO PHARMA AM | Inhalation therapy device |
Nov, 2024
(6 months from now) | |
| US7931212 | SUMITOMO PHARMA AM | Fluid droplet production apparatus and method |
Nov, 2025
(1 year, 7 months from now) | |
| US11278683 | SUMITOMO PHARMA AM | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Aug, 2026
(2 years from now) | |
| US9265900 | SUMITOMO PHARMA AM | Disposable ampoule for an aerosol generating device |
Dec, 2028
(4 years from now) | |
| US10940110 | SUMITOMO PHARMA AM | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations |
Feb, 2029
(4 years from now) | |
| US9789270 | SUMITOMO PHARMA AM | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Oct, 2030
(6 years from now) | |
| US9168556 | SUMITOMO PHARMA AM | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
Sep, 2032
(8 years from now) | |
| US9604018 | SUMITOMO PHARMA AM | Aerosol therapy device |
May, 2033
(9 years from now) | |
| US10376661 | SUMITOMO PHARMA AM | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
Sep, 2035
(11 years from now) | |
| US10688518 | SUMITOMO PHARMA AM | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
Nov, 2036
(12 years from now) | |
| US10744277 | SUMITOMO PHARMA AM | Aerosol delivery device and method of operating the aerosol delivery device |
Dec, 2036
(12 years from now) | |
Lonhala Magnair Kit is owned by Sumitomo Pharma Am.
Lonhala Magnair Kit contains Glycopyrrolate.
Lonhala Magnair Kit has a total of 14 drug patents out of which 3 drug patents have expired.
Expired drug patents of Lonhala Magnair Kit are:
- US6962151
- US7316067
- US8511581
Lonhala Magnair Kit was authorised for market use on 05 December, 2017.
Lonhala Magnair Kit is available in solution;inhalation dosage forms.
Lonhala Magnair Kit can be used as long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), a method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd).
The generics of Lonhala Magnair Kit are possible to be released after 07 December, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using
GLYCOPYRROLATE ingredient
Market Authorisation Date:
05 December, 2017Treatment:
Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd); A method of using an aerosol delivery device to aerosolize glycopyrrolate for the ...Dosage:
More Information on Dosage
LONHALA MAGNAIR KIT family patents
